nal use only
COVID-19
Investor briefing
22 March 2022
Disclaimer
This presentation has been prepared by ResApp Health Limited ("ResApp"). The information contained in this presentation is a professional opinion only and is given in good faith. Certain information in this document has been derived from third parties and though ResApp has no reason to believe that it is not accurate, reliable or complete, it has not
been independently audited or verified by ResApp.
Any forward-looking statements included in this document involve subjective judgment and analysis and are subject to uncertainties, risks and contingencies, many of which are outside the control of, and may be unknown to, ResApp. In particular, they speak only as of the date of this document, they assume the success of ResApp's strategies, and they
onlyare subject to significant regulatory, business, competitive and economic uncertainties and risks. Actual future events may vary materially from the forward-looking statements and the assumptions on which the forward-looking statements are based. Recipients of this document (Recipients) are cautioned to not place undue reliance on such forward- looking statements. ResApp makes no representation or warranty as to the accuracy, reliability or completeness of information in this document and does not take responsibility for updating any information or correcting any error or omission which may become apparent after this document has been issued.
The i formation in this presentation is an overview and does not contain all information necessary to make an investment decision. It is intended to constitute a summary of
certain information relating to the performance of ResApp. The information in this presentation is of a general nature and does not purport to be complete. This presentation sh uld be read in conjunction with ResApp's other periodic and continuous disclosure announcements, which are available at https://www.resapphealth.com.au/investor-
relations/asx-announcements/.
To the extent permitted by law, ResApp and its officers, employees, related bodies corporate and agents (Agents) disclaim all liability, direct, indirect or consequential (and | |
whether or not arising out of the negligence, default or lack of care of ResApp and/or any of its Agents) for any loss or damage suffered by a Recipient or other persons arising | |
use | |
out of, or in connection with, any use or reliance on this presentation or information. | |
This presentation is not an offer, invitation, solicitation or recommendation with respect to the subscription for, purchase or sale of any security, and neither this presentation | |
nor anything in it shall form the basis for any contract or commitment whatsoever. | |
All amounts in Australian dollars unless stated otherwise. | |
nal | 2 |
Agenda
nal use only
COVID-19 | Public | Market & |
research | health | commercial |
& results | context | strategy |
Tony Keating | Professor | Mike Connell |
CEO & Managing Director | Catherine Bennett | VP, Commercial |
3
ResApp's COVID-19 scientific advisory board
nal use only
Prof. Elizabeth Talbot | Prof. Antonio Anzueto | Prof. Catherine Bennett |
Geisel School of Medicine | University of Texas Health | Chair in Epidemiology |
Dartmouth | San Antonio | Deakin University |
Assoc. Prof. Joan Soriano | Assoc. Prof. Mark Howard | Assoc. Prof. Paul Porter |
Hospital Universitario | Director of the Victorian | Curtin University & Joondalup |
de la Princesa Madrid | Respiratory Support Service | Health Campus |
4
COVID-19 | Global stats4 | |
• Coronavirus disease (COVID-19) is an infectious disease | Cases | Deaths |
caused by the SARS-CoV-2 virus | Last 2 weeks 23.8m | 72.9k |
• Globally there has been >6m deaths, at a mortality rate | ||
estimated to be x10 higher than flu2 | ||
only | Overall | |
• At the peak of Omicron, Australians were waiting for up to | ||
7 days for PCR test results (after waiting in queue for up to | ||
6 hours) and rapid antigen tests were difficult to source3 | ||
• PCR and rapid antigen tests | ||
generally require a nasal swab as | Europe | |
use | ||
shown (right) | Americas | |
• Rapid antigen tests are widely used | South-East Asia | |
to screen and detect COVID-19 | ||
Western Pacific | ||
Eastern Mediterranean | ||
1 | ||
nal | Africa | |
1. https://www.nejm.org/doi/full/10.1056/nejmvcm2010260 |
2. https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/coronavirus-disease-2019-vs-the-flu
3. https://www.theage.com.au/politics/victoria/test-samples-no-longer-suitable-after-seven-day-wait-20220108-p59ms1.html
4. https://covid19.who.int (data to 18/3/2022)
Cases Deaths
465m 6.06m
Cases by region
(confirmed)
191,842,819
149,435,827
56,667,275 36,865,816
21,478,988 8,517,888
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
ResApp Health Limited published this content on 22 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 March 2022 02:09:06 UTC.